Tags

Type your tag names separated by a space and hit enter

Evaluation of meloxicam for the treatment of obstructive feline idiopathic cystitis.
J Feline Med Surg 2016; 18(11):925-933JF

Abstract

Objectives The aim of the study was to investigate the effect of the non-steroidal anti-inflammatory drug meloxicam on the clinical course of obstructive idiopathic cystitis in cats in a placebo-controlled clinical study. Methods Thirty-seven cats with obstructive idiopathic cystitis were enrolled. Cats received supportive treatment and an indwelling transurethral catheter for 48 h. On days 0 and 1, all cats received buprenorphine 0.01 mg/kg subcutaneously every 8 h. On day 1, cats were randomly assigned to the meloxicam (n = 18) or placebo group (n = 19) and received meloxicam (0.1 mg/kg on day 1, 0.05 mg/kg on days 2-5) or placebo orally for five consecutive days. Cats were monitored by repeated physical examinations and urinalysis, and with a 5 day questionnaire filled in by the owners after discharge and a telephone interview 3 months after presentation. Parameters for evaluation of treatment success were the occurrence of recurrent urethral obstruction, results of physical examinations and questionnaires. Results Recurrent urethral obstruction occurred in 4/18 cats (22%) in the meloxicam group and 5/19 cats (26%) in the placebo group (P = 1.000). General demeanour and pain on abdominal palpation during hospitalisation improved significantly in both groups (P <0.001). After discharge, with regard to general demeanour, food intake and voiding behaviour, there were no significant differences within or between groups at different time points. Conclusions and relevance Orally administered meloxicam for 5 days did not influence the incidence of recurrent urethral obstruction and the recovery from clinical signs in cats with obstructive feline idiopathic cystitis. The persistence of clinical signs in most of the cats 1 week after initial presentation indicates that symptomatic treatment for a longer period of time is warranted.

Authors+Show Affiliations

1 Clinic of Small Animal Medicine, LMU University Munich, Munich, Germany.1 Clinic of Small Animal Medicine, LMU University Munich, Munich, Germany.1 Clinic of Small Animal Medicine, LMU University Munich, Munich, Germany.2 Clinic for Ruminants, LMU University Munich, Munich, Germany.1 Clinic of Small Animal Medicine, LMU University Munich, Munich, Germany.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

26672127

Citation

Dorsch, Roswitha, et al. "Evaluation of Meloxicam for the Treatment of Obstructive Feline Idiopathic Cystitis." Journal of Feline Medicine and Surgery, vol. 18, no. 11, 2016, pp. 925-933.
Dorsch R, Zellner F, Schulz B, et al. Evaluation of meloxicam for the treatment of obstructive feline idiopathic cystitis. J Feline Med Surg. 2016;18(11):925-933.
Dorsch, R., Zellner, F., Schulz, B., Sauter-Louis, C., & Hartmann, K. (2016). Evaluation of meloxicam for the treatment of obstructive feline idiopathic cystitis. Journal of Feline Medicine and Surgery, 18(11), pp. 925-933. doi:10.1177/1098612X15621603.
Dorsch R, et al. Evaluation of Meloxicam for the Treatment of Obstructive Feline Idiopathic Cystitis. J Feline Med Surg. 2016;18(11):925-933. PubMed PMID: 26672127.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of meloxicam for the treatment of obstructive feline idiopathic cystitis. AU - Dorsch,Roswitha, AU - Zellner,Friederike, AU - Schulz,Bianka, AU - Sauter-Louis,Carola, AU - Hartmann,Katrin, Y1 - 2016/07/10/ PY - 2015/12/17/pubmed PY - 2017/10/11/medline PY - 2015/12/17/entrez SP - 925 EP - 933 JF - Journal of feline medicine and surgery JO - J. Feline Med. Surg. VL - 18 IS - 11 N2 - Objectives The aim of the study was to investigate the effect of the non-steroidal anti-inflammatory drug meloxicam on the clinical course of obstructive idiopathic cystitis in cats in a placebo-controlled clinical study. Methods Thirty-seven cats with obstructive idiopathic cystitis were enrolled. Cats received supportive treatment and an indwelling transurethral catheter for 48 h. On days 0 and 1, all cats received buprenorphine 0.01 mg/kg subcutaneously every 8 h. On day 1, cats were randomly assigned to the meloxicam (n = 18) or placebo group (n = 19) and received meloxicam (0.1 mg/kg on day 1, 0.05 mg/kg on days 2-5) or placebo orally for five consecutive days. Cats were monitored by repeated physical examinations and urinalysis, and with a 5 day questionnaire filled in by the owners after discharge and a telephone interview 3 months after presentation. Parameters for evaluation of treatment success were the occurrence of recurrent urethral obstruction, results of physical examinations and questionnaires. Results Recurrent urethral obstruction occurred in 4/18 cats (22%) in the meloxicam group and 5/19 cats (26%) in the placebo group (P = 1.000). General demeanour and pain on abdominal palpation during hospitalisation improved significantly in both groups (P <0.001). After discharge, with regard to general demeanour, food intake and voiding behaviour, there were no significant differences within or between groups at different time points. Conclusions and relevance Orally administered meloxicam for 5 days did not influence the incidence of recurrent urethral obstruction and the recovery from clinical signs in cats with obstructive feline idiopathic cystitis. The persistence of clinical signs in most of the cats 1 week after initial presentation indicates that symptomatic treatment for a longer period of time is warranted. SN - 1532-2750 UR - https://www.unboundmedicine.com/medline/citation/26672127/Evaluation_of_meloxicam_for_the_treatment_of_obstructive_feline_idiopathic_cystitis_ L2 - http://journals.sagepub.com/doi/full/10.1177/1098612X15621603?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -